SME Times is powered by   
Search News
Just in:   • Sensex surges over 2,100 pts, Nifty above 24,650  • Foreign investors infuse over Rs 14,000 crore into equity in May  • EAM Jaishankar dials counterparts in Asia and Europe, discusses strikes on Pak-based terror camps  • Iran rejects report of proposing direct talks with US  • Singapore issues travel advisory asking citizens to avoid J&K, Pak 
Last updated: 27 Sep, 2014  

India Flag Amblem THMB Cabinet defers decision on relaxing FDI norms in pharma

fdi-retail.jpg
   Top Stories
» Sensex surges over 2,100 pts, Nifty above 24,650
» Foreign investors infuse over Rs 14,000 crore into equity in May
» Sensex, Nifty open nearly flat as geopolitical tensions continue
» Sensex, Nifty gain in early trade as India carries out ‘Operation Sindoor’
» India, UK finalised free trade deal, says PM Modi
SME Times News Bureau | 29 Nov, 2013
The Cabinet Thursday deferred decision on relaxing FDI norms for the housing sector and reducing foreign investment limit to 49 percent in rare and critical areas of the pharma segment, reports media.

The decision on FDI in pharma and housing has been deferred, Information and Broadcasting Minister Manish Tewari said after the Cabinet meeting in New Delhi.

The Department of Industrial Policy and Promotion (DIPP) has proposed to reduce FDI cap from 100 per cent to 49 per cent in the "rare or critical pharma verticals".

Several departments, including the DIPP, have raised serious concerns over continuous acquisitions of Indian drug makers by global multinational firms.

According to sources, three categories have been proposed to define "rare or critical". It includes companies with five or more manufacturing units, and companies with 40 per cent or more market share irrespective of the total number of manufacturing facilities.

"If an entity manufactures multiple products, it will be treated as critical if either of the above two conditions are satisfied for at least one third of the products," said a source.

The DIPP has also proposed incorporating conditions for foreign firms like mandatory investment in R&D and non-compete clause in the shareholders pact.

India at present permits 100 per cent FDI in the pharma sector through automatic approval route in the new projects, but the foreign investment in existing pharma companies is allowed only through FIPB's approval.

Regarding FDI in the housing sector, DIPP has proposed relaxing FDI norms including easing conditions for exit before the three-year lock-in period. It has proposed easing conditions for exit of foreign players before the three-year lock-in period. 
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
84.35
82.60
UK Pound
106.35
102.90
Euro
92.50
89.35
Japanese Yen 55.05 53.40
As on 12 Oct, 2024
  Daily Poll
Do you think Indian businesses will be negatively affected by Trump's America First Policy?
 Yes
 No
 Can't Say
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter